Paclitaxel Resistant and Dependent Cell Lines


The Technology: Dr. Fernando Cabral at the University of Texas Health Science Center at Houston (UTHealth) has developed a series of mutant cell lines with altered sensitivity to antimitotic drugs. Paclitaxel is a drug that binds to polymerized tubulin and inhibits microtubule disassembly. One of the major limitations in using these drugs, however, is the emergence of drug resistant tumor cells. The inventor has found that some tubulin isotypes alter sensitivity to antimitotic drugs by perturbing microtubule assembly, while others have little effect on assembly but increase the binding of specific drugs.

• Wang, Y., and Cabral, F (2005). Paclitaxel resistance in cells with reduced β-tubulin. Biochem. Biophys. Acta 1744, 245-255.
• Kamath, K., Wilson. L., Cabral, F., and Jordan, M.A. (2005). βIII-tubulin induces paclitaxel resistance in association with reduced effects on microtubule dynamic instability. J. Biol. Chem. 280, 12902-12907.
• Wang, Y., Win, S., Blade, K., Cooper, G., Menick, D.R., and Cabral, F. (2006). Mutations at Leucine 215 of β-tubulin affect paclitaxel sensitivity by two distinct mechanisms. Biochemistry, 45, 185 - 194.


UTHealth Ref. No.: 2007-0018
Inventors: Cabral
License Available: world-wide; exclusive or non-exclusive

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Research Materials
For Information, Contact:
Yu-Jane Wu
Senior Licensing Associate
University of Texas Health Science Center At Houston
© 2020. All Rights Reserved. Powered by Inteum